View Author
scopus: 35203964800

Sudhir, K.

(Krishnankutty Sudhir)


stent patient lesion follow-up trial spirit vessel group month study analysis stent thrombosis artery outcome artery lesions 3- year follow-up scaffold event thrombosis everolimus-eluting target randomized signi stent system spirit ii strut result xience death treatment paclitaxel-eluting abbott everolimu value table angiographic 3 years 12 months paclitaxel-eluting stents diameter intervention ef ficacy ficant 1 year revascularization 2 years reduction system eluting 6 months 12- month outcomes id-tlr signi ficantly serruy restenosi lumen santa clara infarction spirit ii trial 3- year outcomes point ficacy safety drug-eluting rvd >2.65 mm ll >13.4 mm ll <13.4 mm difference finite xience v procedure patients randomized bioresorbable segment figure spirit iii group c intravascular 0.0 end points




4 Most Recent Publications

Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents: Pooled analysis from the SPIRIT (Clinical evaluation of the XIENCE v everolimus eluting coronary stent system) and COMPARE (second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) randomized trials (Article)
Claessen, B.E. Smits, P.C. Sood, P. Simonton, C. Stone, G.W. Kereiakes, D.J. Parise, H. Fahy, M. Kedhi, E. Serruys, P.W.J.C. Lansky, A.J. Cristea, E. Sudhir, K.
2011-11-01
Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de Novo Coronary Artery stenosis: 12-month clinical and imaging outcomes (Article)
Serruys, P.W.J.C. Onuma, Y. Windecker, S. Whitbourn, R. Meredith, I. Dorange, C. Veldhof, S. Hebert, K.M. Sudhir, K. Garcia-Garcia, H.M. Ormiston, J.A. Dudek, D. Smits, P.C. Koolen, J. Chevalier, B. Bruyne, B. de Thuesen, L. McClean, D. Geuns, R-J.M. van
2011-10-04
Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents: A pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE v Everolimus Eluting Coronary Stent System in the Treatment of Patients with de Novo Native Coronary Artery Lesions) and SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE v Everolimus Eluting Coronary Stent System [EECSS] (Article)
Caixeta, A. Lansky, A.J. Sood, P. Su, X. Jonnavithula, L. Sudhir, K. Stone, G.W. Serruys, P.W.J.C. Hermiller, J.B. Ruygrok, P.N. Onuma, Y. Gordon, P. Yaqub, M. Miquel-Hébert, K. Veldhof, S.
2010-12-01
3-Year Clinical Follow-Up of the XIENCE V Everolimus-Eluting Coronary Stent System in the Treatment of Patients With De Novo Coronary Artery Lesions. The SPIRIT II Trial (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions) (Article)
Garg, S.A. Serruys, P.W.J.C. Riele, J.A. te Onuma, Y. Dorange, C. Veldhof, S. Miquel-Hébert, K. Sudhir, K. Boland, J.B. Huber, K. Garcia, E.
2009-12-01
  • rss icon RSS Publication Feed
  • foaf icon FOAF Profile